Recombinant interferon alpha‐C for advanced hairy cell leukemia. An Israeli multicenter study

Dan Aderka, Rita Michalevicz, Yair Daniel, Yoram Levo, Dan Douer, Isaac Ben‐Bassat, Bracha Ramot, Matitiahu Shaklai, Miron Prokocimer, Alan Berrebi, Dina Meytes, Hanna Rosenbaum, David Wallach, Michel Revel

Research output: Contribution to journalArticlepeer-review

Abstract

Thirteen patients with advanced hairy cell leukemia were treated with a new subspecies of interferon (IFN): recombinant IFN (rIFN)‐alpha‐C. The timing of the peripheral hematologic remission of individual blood elements was similar to that reported for other interferons, and 60% of patients attained a complete peripheral hematologic remission at 9 months. Two patients relapsed despite a good initial response to IFN. No anti‐IFN antibodies could be detected in their sera. in vitro studies of colony formation from the peripheral blood of all responding patients showed that rIFN‐alpha‐C did not inhibit the growth of colonies but favorably affected the maturation of their elements towards monocytes, granulocytes, and erythroid elements. The relapsing patient examined initially experienced a similar beneficial in vitro response which paralleled his in vivo improvement. During relapse, rIFN‐alpha‐C inhibited both the colony formation and the myelomonocytic differentiation in the in vitro cultures. These findings may suggest that the acquired resistance to IFN in our patient could be due either to an acquired stem cell maturation arrest in response to IFN or to emergence of a new clone indifferent to IFN‐alpha‐C differentiation effect.

Original languageEnglish
Pages (from-to)2207-2213
Number of pages7
JournalCancer
Volume61
Issue number11
DOIs
StatePublished - 1 Jun 1988
Externally publishedYes

Fingerprint

Dive into the research topics of 'Recombinant interferon alpha‐C for advanced hairy cell leukemia. An Israeli multicenter study'. Together they form a unique fingerprint.

Cite this